Insurance hurdles and costs hinder access to blood cancer drugs
Patients with blood cancers often face major insurance hurdles and significant out-of-pocket costs when trying to access specialty oral anticancer medications, according to a new nationwide study led by researchers at the Perelman School of Medicine at the University of Pennsylvania.
Read original article on The Medical News →Related news
-
OnDosis and Adare Pharma Solutions announce strategic collaboration to advance OnDosis's lead U.S. ADHD program
United Kingdom
-
New antibiotic combinations aim to prevent recurrent bacterial vaginosis
United Kingdom
-
Study examines the real-world use of GLP-1 RA drugs in children and young people
United Kingdom
-
Menstrual tracking apps lack evidence of health and performance benefits
United Kingdom
-
Research reveals major impact of climate change on skin health worldwide
United Kingdom
-
COVID fatigue linked to reduced brain blood flow
United Kingdom
-
Long‑acting medicines could make daily tablets a thing of the past for some patients
United Kingdom
-
Autonomous AI could create capacity for thousands more dermatology appointments, real-world study finds
United Kingdom